CLINICAL TRIALS PROFILE FOR AG-881
Clinical Trials for AG-881
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02481154 ↗ | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Active, not recruiting | Agios Pharmaceuticals, Inc. | Phase 1 | This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation. |
| NCT02481154 ↗ | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Active, not recruiting | Institut de Recherches Internationales Servier | Phase 1 | This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation. |
| NCT02492737 ↗ | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | Completed | Agios Pharmaceuticals, Inc. | Phase 1 | The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation |
| NCT03343197 ↗ | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | Active, not recruiting | Agios Pharmaceuticals, Inc. | Phase 1 | Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881. |
| NCT03343197 ↗ | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | Active, not recruiting | Institut de Recherches Internationales Servier | Phase 1 | Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881. |
| NCT03960502 ↗ | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 | Completed | Agios Pharmaceuticals, Inc. | Phase 1 | The purpose of this Phase I, open-label study is to evaluate the absorption, distribution, metabolism, excretion, absolute bioavailability, and to characterize the metabolites of AG-881 in healthy male participants following administration of a single oral dose of [14C] AG-881 and a concomitant intravenous microdose of [13C315N3] AG-881. |
| NCT04015687 ↗ | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults | Completed | Agios Pharmaceuticals, Inc. | Phase 1 | The main purpose of this study is to examine the effect of multiple doses of AG-881 on the pharmacokinetics (PK) of a single dose of lamotrigine in healthy adults. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for AG-881
Condition Name
Clinical Trial Locations for AG-881
Trials by Country
Clinical Trial Progress for AG-881
Clinical Trial Phase
Clinical Trial Sponsors for AG-881
Sponsor Name
